藥事經濟學導論

課程簡介與說明，文獻選讀重點 (上課講義)

PE and Policy/Introduction Glossary and Basic Concept (上課講義)

PE and Policy/1. The Pharmaceutical Industry 1. Chart Pact: Biopharmaceuticals in Perspective. 2. Lenia Long. The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development.

PE and Policy/2. The Biotechnology Industry (p.59~86) 3. How to develop and implement a national drug policy World Health Organization 2001, Geneva. 4. Enhancing Taiwan’s Healthcare Sustainability: A Delphi study on national medicine policy reform. JFMA 2024 Novenber. 123 Suppl 3:S169-S179

PE and Policy/3. Generics and Biosimilars 4. 5. AI in Pharmaceutical Industry (上課講義)

PE and Policy/4. The Global Pharmaceutical Industry PE and Policy/5. The Demand for Pharmaceuticals 6. Global Medicine Spending and Usage Trends ~Outlook to 2025. IQVIA Institute, April 2021. 7. Preview 2021 Outlook to 2026, 14th Edition. Evaluate, July 2021.

PE and Policy/4. The Global Pharmaceutical Industry PE and Policy/5. The Demand for Pharmaceuticals 8. Pharmaceutical Registration in Taiwan (上課講義)

PE and Policy/7. Pharmaceutical Prices (p.193~219) PE and Policy/8. Economic Evaluation of New Drugs (p.220~246) 9. 藥事經濟研究基本概念 (上課講義)

PE and Policy/9. Pricing Pharmaceuticals in a World Environment (p.247~268) 10. Overview of Taiwan’s Biopharmaceutical Market. 2025 生技產業白皮書，經濟部產業發展署， 2025年七月。

11. WHO guideline on country pharmaceutical pricing policies. 2020 WHO, Geneva. 12. Joy Li-Yueh Lee, Michael A. Fischer, William H. Shrank, Jennifer M. Polinski, Niteesh K. Choudhry: A systematic review of reference pricing: Implications for US prescription drug spending. The American Journal of Managed Care 2012; 18(11):e430-e437

13. Olivier J. Wouters, Panos G. Kanavos and Martin McKee. Comparing generic drug markets in Europe and the United States: Prices, volumes, and spending. The Milbank Quarterly 2017, 95(3): 554-601. 14. Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, Aaron S Kesselheim: Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study. BMJ 2018; 360:k831. 15. Andrew W. Mulcathy, Daniel Schwam, Susan L. Lovejoy. International Prescription Drug Price Comparisons_ Estimates Using 2022 Dat, Rand Corporation, 2024

16. 全民健康保險藥品給付項目與支付標準，衛福部中央健康保險署。 17. 黃文鴻、傅凱群、闕辰翰、陳欣宏、沈麗娟*、蔡憶文*: Pharmaceutical Procurement Profit and Universal Health Coverage: Reform to a sustainable healthcare and financing system. J of Formosa Medical Association 2024 Nov:123 Suppl 3:S242-S250.

18. IQVIA White Paper: The Impact of Biosimilar Competition in Europe, 2025 January. 19. Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber: Policies for biosimilar uptake in Europe: An overview. PlosOne, December 28, 2017. Available from: https://doi.org/10.1371/journal.pone.0190147.

PE and Policy/11. Patent Protection (p.303~321) 20. Orphan Drugs in the United States: Providing context and Cost. INQUIVA Institute, October 2017. 21. Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations. INQUIVA Institute, December 2018.

22. 如何評估生技製藥投資計畫?(上課講義)

期末主題心得報告/期末測驗